Por: RTTNews Health December 04, 2023
Exelixis, Inc. () and Arcus Biosciences () have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' tyrosine kinase inhibitor, in combination with AB521. Exelixis is sponsoring STELLAR-009, and Arcus is co-funding the study and providing AB521 for use in the trial. Patient enrollment is expected to begin before the end of 2023.We are excited to partner with Exelixis on the... + full article
RTTNews USA Health September 25, 2023
Coherus BioSciences, Inc. () said the FDA issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA ONBODY, the company's on-body injector presentation of UDENYCA, solely due to an ongoing review of inspection findings at a... + más
Coherus BioSciences Shares Drop 9% on FDA's Application Rejection | MarketWatch
High school scores and top performers from Friday, March 24 | Orlando Sentinel
MarketWatch USA Business August 23, 2023
Netflix Inc.’s stock rose 5.6% to lead S&P 500 gainers, after Oppenheimer analysts said paid programming and advertising should boost revenue by about 40% through fiscal 2025 from fiscal 2022. United Parcel Services Inc.‘s stock added 1% after Abercrombie & Fitch Co.’s... + más
Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate
A few things to know about the Peloton bike recall | The Boston Globe
Fox Business USA Business April 16, 2023
Check out what's clicking on FoxBusiness.com Merck & Co. is reportedly in talks to acquire Prometheus Biosciences Inc. The talks are said to be in the late stage with a deal possibly announced as soon as Sunday, according to The Wall Street Journal.A deal is not certain and... + más
Merck to acquire Prometheus Biosciences for $10.8B | Fox Business
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
Check out what's clicking on FoxBusiness.com Merck & Co. is acquiring Prometheus Biosciences in a $10.8 billion deal. All the shares of Prometheus Biosciences will be acquired by a subsidiary of Merck for $200 per share.. promising immune disease treatments. The acquisition... + más
Merck in talks to acquire Prometheus Biosciences: report | Fox Business
ABC News USA Business March 21, 2023
NEW YORK -- Stocks that traded heavily or had substantial price changes Monday: UBS Group AG., up 60 cents to $18.80. The banking giant is buying troubled Swiss rival Credit Suisse for almost $3.25 billion.New York Community Bancorp Inc., up $2.07 to $8.61.The bank agreed to buy... + más
First Republic execs reportedly dumped $12M in stock before bank chaos | New York Post
First Republic Shares Crater To All-Time Low As Bank Reportedly Taps JPMorgan To Explore Possible Sale | Forbes
Forbes USA Business December 22, 2022
C16 Biosciences founders in the company’s office in Manhattan, NY.C16 Biosciences Shara Ticku was boarding a flight to Singapore for a work trip when her company handed her a stack of N95 masks. This was July 2013, when most of us had never even tried on a face mask. At that... + más
Palm oil is in almost everything, and it's devastating rainforests. This Bill Gates-backed company used microbes to create an alternative | CNBC
Will Adams’ post-COVID blueprint for NYC work in Midtown? New Yorkers: Fuhgeddaboudit | New York Daily News
CNBC USA Tech November 03, 2022
Shara Ticku and David Heller, co-founders of C16 Biosciences.Photo courtesy C16 Biosciences.In July 2013, traveled to Singapore on a work trip for Goldman Sachs. The investment bank made her bring N95 masks to protect her from the terrible air quality at the time.I land in... + más
Ancient Microbes Could Still Be Living on Mars | Time
Nick Gates snaps to Daniel Jones at Wednesday’s practice: ‘I’m happy for him’ | New York Daily News
About iurex | Privacy Policy | Disclaimer |